MARKET

CFMS

CFMS

Conformis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3723
+0.0321
+9.44%
Pre Market: 0.4200 +0.0477 +12.81% 08:14 05/16 EDT
OPEN
0.3538
PREV CLOSE
0.3402
HIGH
0.3881
LOW
0.3488
VOLUME
10.65K
TURNOVER
--
52 WEEK HIGH
1.955
52 WEEK LOW
0.2871
MARKET CAP
69.03M
P/E (TTM)
-9.2843
1D
5D
1M
3M
1Y
5Y
Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chie...
GlobeNewswire · 6d ago
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:25
Recap: Conformis Q1 Earnings
  Conformis (NASDAQ:CFMS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 11:26
Conformis Q1 EPS $(0.09) Misses $(0.07) Estimate, Sales $15.60M Beat $14.01M Estimate
Conformis (NASDAQ:CFMS) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year. The company reported
Benzinga · 05/04 11:20
ConforMIS GAAP EPS of -$0.09 misses by $0.02, revenue of $15.6M beats by $1.59M
ConforMIS press release (NASDAQ:CFMS): Q1 GAAP EPS of -$0.09 misses by $0.02. Revenue of $15.6M (+12.7% Y/Y) beats by $1.59M. Outlook: "We expect our second quarter product revenue to be
Seekingalpha · 05/04 11:13
-- Earnings Flash (CFMS) CONFORMIS Reports Q1 Revenue $15.6M, vs. Street Est of $14M
MT Newswires · 05/04 07:18
SeaSpine Holdings (SPNE) Reports Q1 Loss, Tops Revenue Estimates
SeaSpine (SPNE) delivered earnings and revenue surprises of -28.57% and 3.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 21:45
Earnings Preview: Conformis
Conformis (NASDAQ:CFMS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Conformis will report an earnings per share (EPS) of $-0.07.
Benzinga · 05/03 16:10
More
No Data
Learn about the latest financial forecast of CFMS. Analyze the recent business situations of Conformis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CFMS stock price target is 1.917 with a high estimate of 2.000 and a low estimate of 1.750.
High2.000
Average1.917
Low1.750
Current 0.3900
EPS
Actual
Estimate
-0.020.050.120.19
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 134
Institutional Holdings: 81.71M
% Owned: 44.06%
Shares Outstanding: 185.43M
TypeInstitutionsShares
Increased
16
16.02M
New
15
5.09M
Decreased
19
11.38M
Sold Out
15
1.40M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.39%
Healthcare Equipment & Supplies
-0.13%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Fallon
President/Chief Executive Officer/Director
Mark Augusti
Chief Financial Officer/Treasurer
Robert Howe
Chief Operating Officer
Michael Fillion
Secretary
Denise Pedulla
Independent Director
Carrie Bienkowski
Independent Director
Philip Johnston
Independent Director
Bradley Langdale
Independent Director
Michael Milligan
No Data
No Data
About CFMS
ConforMIS, Inc. is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, to each patient's unique anatomy. The Company's products include iUni, iDuo, iTotal CR, iTotal PS, iTotal Identity and Conformis Cordera Hip System. Its iFit technology platforms include Fit Design, its algorithms and computer software that used to design personalized implants and associated single-use, patient-specific instrumentation, which referred to as iJigs, based on a computed tomography scan of the patient and to prepare a surgical plan personalized for the patient that called as iView; iFit Printing, a three-dimensional, printing technology that used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities. It offers a line of the sterile, personalized knee and hip implants and single-use instruments delivered to hospitals.

Webull offers kinds of ConforMIS Inc stock information, including NASDAQ:CFMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFMS stock methods without spending real money on the virtual paper trading platform.